Press Releases Apollomics, Inc.

Equities

APLM

KYG0411D1079

Delayed Nasdaq Other stock markets 01:18:41 31/05/2024 am IST			5-day change	1st Jan Change
0.31 ^USD	+4.03%		+19.81%	-67.10%

08/05	Apollomics, Inc. Appoints Robert Lin to the Board of Directors	CI
08/05	Apollomics, Inc. announced that it has received $5.75 million in funding	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Apollomics Announces Presentation at the 2024 BIO International Convention	29/05	GL
Apollomics Announces Presentation at the 2024 BIO International Convention	29/05	AQ
Apollomics Announces Private Placement Financing and Addition to Board of Directors	09/05	GL
Apollomics Announces Private Placement Financing and Addition to Board of Directors	09/05	AQ
Apollomics : April 2024 Corporate Presentation	25/04	PU
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene	25/04	GL
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting	10/04	GL
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting	02/04	GL
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results	28/03	GL
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results	28/03	AQ
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024	26/03	GL
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024	26/03	AQ
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer	04/03	GL
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer	04/03	AQ
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02	GL
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	20/01	GL
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	20/01	AQ
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference	18/01	GL
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia	03/01	GL
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia	03/01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Apollomics, Inc.

Equities

APLM

KYG0411D1079

Press Releases

Filters